key: cord-0974773-vxgqitwe
authors: Pawar, Anil; Russo, Maria; Rani, Isha; Goswami, Kalyan; Russo, Gian Luigi; Pal, Amit
title: A critical evaluation of risk to reward ratio of quercetin supplementation for COVID‐19 and associated comorbid conditions
date: 2022-04-08
journal: Phytother Res
DOI: 10.1002/ptr.7461
sha: c54cfd4fd4c4b24a4cf34056313e26c48eb6b427
doc_id: 974773
cord_uid: vxgqitwe

The interim results of the large, multinational trials on coronavirus disease 2019 (COVID‐19) using a combination of antiviral drugs appear to have little to no effect on the 28‐day mortality or the in‐hospital course. Therefore, there is a still vivid interest in finding alternate re‐purposed drugs and nutrition supplements, which can halt or slow the disease severity. We review here the multiple preclinical studies, partially supported by clinical evidence showing the quercetin's possible therapeutic/prophylaxis efficacy against severe acute respiratory syndrome coronavirus (SARS‐CoV) as well as comorbidities like chronic obstructive pulmonary disease (COPD), diabetes mellitus, obesity, coagulopathy, and hypertension. Currently, 14 interventional clinical trials are underway assessing the efficacy of quercetin along with other antiviral drugs/nutritional supplements as prophylaxis/treatment option against COVID‐19. The present review is tempting to suggest that, based on circumstantial scientific evidence and preliminary clinical data, the flavonoid quercetin can ameliorate COVID‐19 infection and symptoms acting in concert on two parallel and independent paths: inhibiting key factors responsible for SARS‐CoV‐2 infections and mitigating the clinical manifestations of the disease in patients with comorbid conditions. Despite the broad therapeutic properties of quercetin, further high power randomized clinical trials are needed to firmly establish its clinical efficacy against COVID‐19.

indirectly involved in antiinflammatory and anti-lung injury effects (Zhou et al., 2020) .

In vitro and computational studies, or their combination (L. Chen et al., 2006; Ryu et al., 2010; Yi et al., 2004) showed promising evidence that quercetin could be effective against SARS virus infection and consequent clinical outcomes (reviewed in Savant, Srinivasan, & Kruthiventi, 2021) . It is intriguing to note that ACE2 receptor, expressed in organs such as lung, kidney, heart, intestine, and endothelial cells (Ferrario et al., 2005) , mediates the SARS-CoV-2 infection in humans. Quercetin can target ACE2 expression (ACE2 gene expression is required for SARS-CoV-2 entry into human cells) (Glinsky, 2020) by interfering with Spike-ACE2 binding and interacting with papain-like protease (PL pro ) ( Figure 1 ). The net result of quercetin action is a significant reduction of the SARS-CoV-2 potential infectivity (Huang et al., 2020a) . PL pro is a crucial enzyme of CoV implicated in the viral spread and immune evasion mechanisms (Shin et al., 2020) . Yi et al. (2004) developed HIV-luc/SARS pseudotyped virus and carried out in vitro virus entry inhibition assay using quercetin and another related flavonoid, luteolin. Both these flavonoids were effective in inhibiting the entry of SARS-CoV inside the host cell.

Quercetin as well as its derivatives (luteolin, quercetin-3-β-galactoside, and epigallocatechin gallate) were observed to inhibit the activity of SARS-CoV proteases. Ryu et al. (2010) in an in vitro study observed that both luteolin and quercetin inhibited the enzyme activity of chymotrypsin-like protease (3CL pro ), also known as the main protease (M pro ) of SARS-CoV, which plays a pivotal role in viral replication and infection processes. However, their inhibitory activity was lower than amentoflavone, a flavonoid derived from Torreya nucifera plant (Ryu et al., 2010) . Nguyen et al. (2012) It also targets ACE2 expression, and thus affects viral entry. Simultaneously, quercetin affects 3CL pro (viral main proteinase), an essential component of the viral replication cycle and thus hampers the activation of individual proteins. Quercetin also acts as Zn ionophore to increase intracellular Zn concentration which inhibits viral RdRp activity in a dose-dependent manner. 3CL pro , coronavirus main proteinase; ACE2, angiotensin-converting enzyme 2; NSPs, non-structural proteins, ppa1/ab2, polyproteins a1/ab2; RBD, receptor-binding domain; RdRp, RNA-dependent RNA polymerase; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TMPRSS2, transmembrane serine protease 2; Zn, zinc of a chemical library consisting of about 150 compounds, identified quercetin as a potent inhibitor of SARS-CoV-2 3CL pro ([K i~7 μM], Abian et al., 2020) . In a different study, quercetin-3-β-galactoside, a quercetin derivative, was identified as an inhibitor of SARS-CoV 3CL pro using mutagenesis studies, molecular docking, surface plasmon resonance, and fluorescence resonance energy transfer bioassays (L. Chen et al., 2006) .

The effectiveness of quercetin not only against SARS-CoV, but also SARS-CoV-2 has been suggested in a thought-provoking prediction study showing that the hypothetical tripartite combination of vitamin-D, quercetin, and estradiol can be putative COVID-19 mitigation agents. The authors of this computational work used supercomputer SUMMIT drug-docking screen and Gene Set Enrichment Analyses of expression profiling experiments and found quercetin and the structurally similar flavonoid, luteolin, as one of the top-scoring candidate therapeutics that can serve as scaffolds for the development of possible SARS-CoV-2 infection inhibitors (Glinsky, 2020) . This finding has been supported by in vitro evidence indicating that both luteolin and quercetin could impede the entry of the SARS virus into the cells (Yi et al., 2004) .

Besides these actions, quercetin supplementation will also help to circumvent the zinc deficiency problem in COVID-19 infected/elderly subjects as it acts as a zinc ionophore (Dabbagh-Bazarbachi et al., 2014) , thereby helping in increasing the labile intracellular zinc concentration ( Figure 1 ). It is noteworthy to mention that zinc has been shown to inhibit RNA-dependent RNA polymerase (RdRp) activity of the SARS virus under in vitro conditions in a dose-dependent manner (reviewed in Read, Obeid, Ahlenstiel, & Ahlenstiel, 2019) .

However, the hypothesis that quercetin along with zinc supplementation can be beneficial for COVID-19 treatment/prophylaxis is not clinically tested yet.

In summary, accumulating evidence deriving from both computational and experimental studies suggests that quercetin, as other phenolic compounds, can act at multiple levels to inhibit or reduce the infectivity of coronaviruses including SARS-CoV and SARS-CoV-2 although only very recently the clinical efficacy of these treatments have been explored (Bernini & Velotti, 2021; Di Pierro, Derosa, et al., 2021; Di Pierro, Iqtadar, et al., 2021; Rondanelli et al., 2022; Shohan et al., 2022) .

Emerging data clearly states that aging as well as various other concomitant conditions, such as COPD, diabetes, obesity, cardiovascular disease (CVD), and hypertension enhance the disease severity and mortality among COVID-19 patients (A. K. Singh & Misra, 2020; B. Wang, Li, Lu, & Huang, 2020; Wu & McGoogan, 2020) . In the following sub-sections, we will analyze the potential beneficial role of quercetin in these conditions following COVID-19 infection.

Epidemiological data on the mortality rate of COVID-19 patients clearly demonstrate that the elderly population, especially in the presence of co-morbidities, has a greater risk of death than the rest of the younger population in different countries (Ioannidis, Axfors, & Contopoulos-Ioannidis, 2020) . If the simplest explanation implies that old people are at risk for their "intrinsic" frailty due to the presence of co-morbidities, such as diabetes, hypertension, cancer, and cardiovascular pathologies, this medical evidence is still poorly explored from a biological point of view (Blagosklonny, 2020) . The big scientific challenge is to understand why the aging process is strictly correlated to SARS-CoV-2 deleterious infection. A possible answer resides in the biological process known from the early '60 and targeted as one of the "hallmarks of aging and cancer": senescence (Roy et al., 2020) .

Cellular senescence, first reported in 1961 by Hayflick and Moorehead (1961) is a cell condition that involves an irreversible replicative arrest, sustained viability with resistance to apoptosis, and, frequently, increased metabolic and inflammatory activity known as SASP (Senescence Associated Secretory Phenotype). SASP includes a myriad of inflammatory, pro-apoptotic, insulin resistance inducing cytokines, such as tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-8, transforming growth factor (TGF)-β family members, all contributing to fibrosis, stem cell and progenitor dysfunction, increased plasminogen activator inhibitor-1 (PAI) that can cause blood clotting and fibrosis (Kirkland & Tchkonia, 2017; Roy et al., 2020) .

Mechanistically, there are multiple factors inducing a senescent state in cells. These intrinsic or environmental factors alter tissue homeostasis in physiological or pathological conditions: DNA damage, telomere shortening after every cell division, proteolytic stress due to an alteration in autophagy process, oncogene activation inducing replicative stress, reactive metabolites such as ROS, inflammatory cytokines, and pathogen-associated molecular patterns (PAMPs) (Roy et al., 2020; Zhou et al., 2020) . The senescence-inducing factors activate downstream biochemical pathways involving cell cycle proteins, such as p16 INK4 and retinoblastoma protein (Rb), p53, and p21 CIP1 in others (Kirkland & Tchkonia, 2020; Roy et al., 2020) . Finally, after days or weeks, senescence leads to replicative arrest with altered expression of hundreds of genes, as well as epigenetic changes.

From a mechanistic point of view, a recent work demonstrated that, in a mouse model of SARS-CoV-2-related β-coronavirus, quercetin and Dasatinib targeted senescent cells and, acting on PAMP. Their combination significantly reduced mortality, cellular senescence, inflammatory markers, and increased antiviral antibodies (Camell et al., 2021) .

Morphologically, senescent cells appear flatted and enlarged, express active β-galactosidase in lysosomes, and can appear at any point during life in vertebrates, even in 32 cell stage human blastocysts (Meuter et al., 2014) . Typically, senescent cells accumulate in multiple tissues during the latter part of the lifespan, such as fibroblasts in the skin and adipocytes in adipose tissue. Senescent cells are also present in many "pathological" tissues such as in pulmonary fibrosis, endothelium membranes and cardiac cells in CVD, and adipose tissue in diabetes and obesity (Kirkland & Tchkonia, 2020) .

Kirkland and Tchkonia proposed a "Unitary Theory of Fundamental Aging Processes" according to which "accelerating or targeting any one fundamental ageing process (e.g., cellular senescence) genetically or with drugs" should affect the entire aging mechanism (Kirkland & Tchkonia, 2017 . This hypothesis suggests a strict correlation between the distribution of senescent cells in the organism and healthspan. Therefore, a delayed accumulation of p16 INK4 positive senescent cells in mice in which healthspan was extended by caloric restriction led to the idea that senescent cells could be eliminated by a selective drug or drug combinations called "senolytics" (Krishnamurthy et al., 2004) . To develop the first senolytic drugs, the Kirkland group utilized a strategy based on RNAi screening and previous observation that senescent cells are resistant to apoptosis (E. Wang, 1995) . This approach allowed the identification of different molecules called "senotherapeutics": the BH3 "mimetics" ABT-263 (Navitoclax), the tyrosine kinase inhibitor Desatinib, and natural flavonoids such as quercetin and fisetin (Kirkland & Tchkonia, 2020; Russo et al., 2020) . The latter have been included in clinical trials protocols (phase1-2) aimed to ameliorate age-related pathologies such as pulmonary fibrosis, osteoarthritis, and diabetic chronic kidney disease (Kirkland & Tchkonia, 2020) .

It is worthwhile to mention that senescence and stem cell exhaustion are processes showing considerable overlaps being the latter involved in the decline of the tissue regenerative potential, a characteristic of aging (L opez-Otín, Blasco, Partridge, Serrano, & Kroemer, 2013) . To what extent coronavirus infections induce senescence/exhaustion, or target previously senescent cells is not clearly defined. A recent pivotal article (S. Lee et al., 2021) reported that SARS-CoV-2 evoked cellular senescence as a primary stress response in infected cells. The authors also showed that senolytics, such as navitoclax (BH3 mimetic) and a combination of Dasatinib plus quercetin selectively eliminated virus-induced senescent cells, mitigated COVID-19-reminiscent lung disease, and reduced inflammation in SARS-CoV-2-infected hamsters and mice.

In the specific case of elderly (comorbid) COVID-19 patients, selective elimination of infected "senescent" cells in the lung by quercetin alone or in association with BH3 mimetics or Desatinib may be critical for the termination of viral infection without deleterious side effects. However, several unknown aspects of senescence-related to virus infection persist. Ten years ago, cellular senescence has been also described as an anti-viral mechanism. Indeed, the release of proinflammatory mediators and cell cycle arrest characterizing senescent cells are very similar to the features observed by many cells during an antiviral response (Reddel, 2010) .

In the specific case of SARS-CoV-2 infection, many questions should be experimentally solved: are senescent cells a "favorite" target of coronavirus infection in the respiratory tissues due to the presence of cellular receptors, such as ACE2 or cluster of differentiation (CD)-26 (Sargiacomo, Sotgia, & Lisanti, 2020) ? In fact, ACE2 is a known inhibitor of cell proliferation and the angiotensin system is upregulated in both premature and replicative senescence and quercetin is able to interact with this key cellular receptor. To reinforce this hypothesis, MERS-CoV cellular receptor CD26 (also called dipeptidyl-peptidase IV, DPP4), is known to be a bona fide cell surface marker of senescent cells (Sargiacomo et al., 2020) .

On the opposite, could senescence be a mechanism that cells use to escape viral spreading through SASP? Alternatively, could SASP be a sort of hyperactivity due to immune-senescence resulting in the socalled cytokine storm? CD8 + cytotoxic lymphocyte senescence is associated with critical telomere shortening and induces a state of "hyper-function" with evasion of apoptosis, increased secretion of pro-inflammatory cytokines and loss of surface CD28, a costimulatory receptor necessary for the mobilization of targeted T-cell immune responses (Dock & Effros, 2011) . The presence of this type of lymphocyte circulating in the blood of patients affected by COVID-19 could be useful in vivo marker to test the efficacy of senolytics in future clinical trials.

These questions remain unexplored in SARS-CoV-2 infection.

Kirkland's group observed that the senolytic flavonoid fisetin was able to reduce mortality in mice infected with mouse β coronavirus. If this unpublished study and the hypothesis that COVID-19 viral antigens exacerbate the SASP in human senescent cells will be confirmed (Kirkland & Tchkonia, 2020) , it may represent strong scientific evidence to support the human clinical trials just approved by the FDA. 1 These trials are based on natural flavonoids such as quercetin and fisetin in older hospitalized COVID-19 patients to prevent progression to cytokine storm and acute respiratory distress syndrome (ARDS).

Hopefully, if positively concluded, these studies will demonstrate the efficacy of senotherapeutics based on natural molecules, such as quercetin or fisetin, to enrich the pharmacological arsenal of senolytic drugs (azithromycin) against SARS-CoV-2 and possibly other future coronaviruses variants (Malavolta, Giacconi, Brunetti, Provinciali, & Maggi, 2020) . Indeed, the approach of senolytic drugs is not to attack a specific virus or to boost the immune system by specific targeting, rather it is aimed to improve health, including immune health, by targeting senescence, one of the hallmarks of aging biology. Of note, "the Geroscience approach is not specific to COVID-19, but once tried and proven, it would be effective against any future pandemics or epidemics" (Sierra, 2020) .

In conclusion, the evidence reported in this section demonstrates that targeting senescent cells using senolytic drugs significantly reduced mortality, cellular senescence, and inflammatory markers and increased antiviral antibodies following infection by SARS-CoV-2 and other viruses.

COPD is a highly diffuse disease whose morbidity and mortality cause represent the fourth cause of death after ischemic heart disease, cerebrovascular disease (stroke), and HIV/AIDS (Mathers & Loncar, 2006) . COPD can be considered a multifactor disease with tobacco smoking (active and passive) and air pollution exposure representing the strongest risk factors (Lange, Ahmed, Lahmar, Martinez, & Bourdin, 2021) .

At cellular level, COPD is associated with changes in the airway epithelium of both progenitors and differentiated cells. Following smoke exposure, the reprogramming and proliferation of basal cells cause aberrant differentiation leading to exhaustion of progenitors cells, an increase of squamous cell numbers, and production of proinflammatory cytokines and other molecular mediators responsible for the emphysematous destruction of the alveolar structure (Lange et al., 2021) .

Following the recent COVID-19 pandemic, clinical observations indicate that a proportion of patients can develop pneumonia and acute severe respiratory failure associated with higher mortality (Zhou et al., 2020) . In this scenario, COPD patients have been identified as a high-risk sub-group who need to remain protected from viral transmission (Higham, Mathioudakis, Vestbo, & Singh, 2020) . In fact, the observations that COPD patients show an increased pulmonary expression of the SARS-CoV-2 receptor, ACE2, (Smith et al., 2020) and their features of endothelial cell dysfunction and increased coagulopathy (Vaidyula, Criner, Grabianowski, & Rao, 2009) , provide molecular and physio-pathological explanations of the increased susceptibility of COPD patients to COVID-19 infection and associated morbidity (Higham et al., 2020) .

Early in 2003, it was reported that resveratrol inhibited cytokine release in alveolar macrophages isolated from COPD patients (Culpitt et al., 2003) . Since then, the role of polyphenols in COPD has been largely studied and proceeded in parallel with the "antioxidant hypothesis" in the therapeutic and preventive approach to COPD treatment (Rahman, 2006; Rahman & Adcock, 2006) . In those years, it was suggested that dietary polyphenols could ameliorate COPD conditions by multiple mechanisms relaying on inhibiting nuclear factor kappa B (NF-κB) activation, histone acetylation, the release of proinflammatory cytokine (Rahman, 2006; Rahman & Adcock, 2006) .

Although this initial enthusiasm has not been fully supported by intervention studies and currently no nutritional recommendations for COPD management have been formally published, the role of polyphenols in maintaining lung function and preventing respiratory diseases remain of great interest (Scoditti, Massaro, Garbarino, & Toraldo, 2019) .

Quercetin is among the polyphenols identified as being potentially effective against COPD ( Figure 2 ). Originally, it was observed that this flavonol and its derivatives inhibited the phosphodiesterase (PDE)-4, the PDE isoenzyme present in airway tissues and immune cells with relevant functions to the pathogenesis of asthma. This suggested the potential effectiveness of quercetin also in the therapy of COPD alone or in association with other PDE4 inhibitors (Chan et al., 2008) . However, it must be underlined that the inhibitory activity was assayed on enzymes purified from guinea pig tissues and no in vivo treatment with quercetin or its derivatives was performed. This initial observation was confirmed later by a study designed to assess the capacity of quercetin to induce bronchorelaxation by preventing the PDE4-dependent degradation of cyclic adenosine monophosphate (cAMP) in myograph studies using ex vivo A/J mouse tracheas (Townsend & Emala Sr, 2013 ). In the same study, the authors reported that nebulization of quercetin (100 μM) induced bronchorelaxant effects when administered acutely before the methacholine challenge (Townsend & Emala Sr, 2013) .

Several works confirmed the bronchodilator capacity of quercetin on human airway smooth muscle (ASM) in obstructive lung diseases such as asthma and COPD. As an example, quercetin, at micromolar concentrations (50-100 μM), reduced current mediated by L-type voltage-dependent Ca 2+ channels (LVDCCs) in single ASM cells isolated from BALB/c mouse tracheal smooth muscle and lowered precontraction induced by acetylcholine chloride (ACH) in human bronchial ASM strips (Luo et al., 2018) . At comparable concentrations, quercetin reduced reactive oxygen species (ROS) and nitric oxide (NO) production in J774A.1 alveolar macrophage exposed to cigarette smoke extract. The same antioxidant effect of quercetin (10 mg/kg/ day) was supposed in C57BL/6 mice exposed to cigarette smoke (da Silva Araújo et al., 2020). Administration of 0.5 mg of quercetin daily for 10 days in elastase/lipopolysaccharide (LPS)-exposed mice, which mimic the typical features of COPD resulted in reduced emphysema, lung inflammation, goblet cell metaplasia, and expression of pro-inflammatory cytokines, all markers of progressive COPD (Ganesan et al., 2010) .

The preclinical evidence that quercetin could be effective in COPD and other obstructive lung diseases has been recently corroborated by a randomized, double-blind, placebo-controlled phase I clinical trial on 10 eligible subjects with COPD. Here, a dose-escalation administration of quercetin (500, 1,000, or 2,000 mg/day for 1 week) was well tolerated with no serious adverse events or significant changes in lung functions (forced expiratory volume in 1 s and forced vital capacity) and blood parameters (white blood cells, platelets and fasting glucose) (Han, Barreto, Martinez, Comstock, & Sajjan, 2020) .

Unfortunately, due to the limited number of subjects in each arm, statistical significance was not performed in this study.

In conclusion, although to our knowledge no studies have been published on quercetin in COPD patients affected by COVID-19, it is of interest that in C57BL/6 mice, where a mild COPD-like lung disease was induced, infection by rhinovirus (RV) increased inflammatory scores (peribronchial and perivascular inflammation, alveolar inflammation, and emphysema). These effects were reduced or abolished by quercetin supplementation (0.1% quercetin in the diet) 10 days prior to RV infection (Farazuddin et al., 2018) . This result is even more important considering that RV infection exaggerates respiratory illness in COPD patients making the disease more severe and prolonged (Mallia et al., 2011) .

Diabetes is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both (American Diabetes Association, 2010). The global prevalence of diabetes is very high as there were nearly 415 million people were affected with diabetes in 2015 (Zimmet, 2017) . Diabetes patients have an enhanced incidence of atherosclerotic cardiovascular, peripheral arterial, and cerebrovascular disease along with hypertension and abnormalities of lipoprotein metabolism. If uncontrolled, diabetes may lead to stupor, coma, and even death (Craig, Hattersley, & Donaghue, 2009; Galtier, 2010) .

Prevailing data from existing literature suggest that diabetes itself is not a risk factor for COVID-19; however, it may augment the disease severity in critically ill patients as compared to non-diabetic patients (Pugliese, Vitale, Resi, & Orsi, 2020) . As ACE2 receptors are also expressed by pancreatic beta cells (Hamming et al., 2004) , SARS-CoV-2, by interfering with glucose metabolism, may create more complications in diabetes patients, or even lead to the onset of new diabetes in infected subjects (Rubino et al., 2020) . Conversely, complications associated with diabetes involving diabetic ketoacidosis and hyperosmolarity may result in an enhanced risk of COVID-19 severity (Chee, Ng, & Yeoh, 2020) . In diabetic persons, enhanced ROS and oxidative stress lower insulin secretion and augment hyperglycemia, which in turn resulting pancreatic β-cell death (H. Patel, Chen, Das, & Kavdia, 2013) . Studies in COVID-19 patients have established that various comorbidities including obesity, hypertension as well as CVD, and chronic kidney disease (CKD) are more common in diabetes patients than in non-diabetes ones (Yan et al., 2020b; Zhu et al., 2020b) .

Several animal studies reported the ability of quercetin to improve glycemic control in both type-1 as well as type-2 diabetes Kim et al., 2011) . Dai et al. (2013) observed that quercetin reduced the blood sugar significantly by stimulating AMP-activated protein kinase (AMPK; a crucial manager of entire body-energy homeostasis) mediated glucose uptake by skeletal muscles and enhanced Glucose transporter type 4 (GLUT4) expression F I G U R E 2 Protective effects of quercetin in COPD. External stimuli or inflammatory cells directly generate ROS which may participate in the direct damage to lung cells, mucus hypersecretion, and accumulation of inflammatory cells (including neutrophils, and macrophages) which further results in exacerbation of ROS, responsible for the induction of redox-sensitive transcription factors, particularly, NF-κB and p38MAPK. Subsequently, it leads to the production of pro-inflammatory cytokines (IL-6, IL-8, IL-1, and TNF-α) and thereby causes the migration primarily of neutrophils from circulation to the inflammatory site, which causes proteases induction, known for airways remodeling and inflammation and thereby contributes to the pathogenesis of COPD. PDE4 reduces cAMP levels in neutrophils and indirectly favors the secretion of inflammatory components through several signaling mechanisms. Quercetin can directly target PDE4 expression and increase cAMP levels which further alleviate inflammatory response. AP1, activator protein 1; cAMP, cyclic adenosine monophosphate; COPD, chronic obstructive pulmonary disease; EPAC, exchange proteins activated by cAMP; JNK1, c-Jun N-terminal kinase; IL, interleukins; NF-κB, nuclear factor kappa-light-chainenhancer of activated B cells; p38 MAPK, p38 mitogen-activated protein kinases; PDE4, phosphodiesterase 4; PKA, protein kinase A; ROS, reactive oxygen species; TNF-α, tumor necrosis factor-alpha ( Figure 3 ). Hamilton et al. (2018) also reported similar effects of quercetin, which triggered the uptake of glucose in C2C12 skeletal muscles in vitro through a mechanism involving AMPK. In mice, quercetin, by activating the AMPK complex, increases the intracellular levels of AMP or AMP-ATP ratio, reduces oxidative destruction, and enhances the uptake of glucose (Antonioli et al., 2016) .

Quercetin enhances glucose uptake by interfering with glucose transport and insulin-receptor signaling (Dhanya, Arya, Nisha, & Jayamurthy, 2017) . In fructose-streptozotocin (STZ)-nicotinamideinduced diabetic rats, quercetin counteracted the negative effects of oxidative stress, inflammation, and apoptosis in the heart (Roslan, Nelli Giribabu, Karim, & Salleh, 2017) . In the same rat model, the treatment with quercetin and resveratrol preserved the action of hepatic glucose metabolic enzymes as well as the structure of pancreatic β-cells (Yang & Kang, 2018) . Another study reported that the dietary consumption of quercetin decreases the possibility of type-2 diabetes (Song, Manson, Buring, Sesso, & Liu, 2005) . Diet-induced insulin resistance can be reduced by long-term dietary intake of quercetin, and it also upregulates peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC1α) in skeletal muscles to improve mitochondrial function (Henagan, Lenard, Gettys, & Stewart, 2014) to support insulin action. According to this observation, the meta-analysis of Bule, Abdurahman, Nikfar, Abdollahi, and Amini (2019) indicated that quercetin was able to reduce the serum glucose level at doses ranging between 10 and 50 mg/kg.

In conclusion, the evidence gleaned in this section exhibits that quercetin lowers blood glucose levels by different mechanisms. However, no studies have been published on the effect of quercetin in diabetic patients affected by COVID-19.

Obesity along with overweight presents a major public health challenge affecting nearly a third of the world's population (Hruby & Hu, 2015) . It is a complex, multifactorial disease involving the unnecessary accumulation of adipose tissue. A higher level of infectious disease watchfulness is needed for such subjects because there is always a possibility of the development of various risk factors, such as diabetes mellitus, CVD, hypertension, and dyslipidemia (Panuganti, Nguyen, & Kshirsagar, 2020) . Patients with severe obesity as well as those with weight-related comorbidities, such as CVD, diabetes, kidney, and liver ailments are at higher risk of COVID-19 infection (A. K. Singh & Misra, 2020) . Manifestations caused by these comorbidities may result in an improper immune response against the virus and may reduce patient response to general COVID-19 therapy F I G U R E 3 The anti-diabetic or anti-glucose potential of quercetin. Quercetin controls blood glucose homeostasis by interacting with several molecular targets in the pancreas, liver, and skeletal muscle. Quercetin reverses the oxidative damage caused by ROS in the pancreas and promotes β cell regeneration which eventually causes over secretion of insulin to regulate blood glucose. In the liver, quercetin upregulates the expression of antioxidant/defensive genes by increasing the binding of Nrf2 to ARE which further abrogates the oxidative damage induced by ROS. It also increases the activity of the GK enzyme and thereby influences several downstream metabolic pathways, such as enhanced glycogen and fatty acids biosynthesis, responsible for increased glucose storage. In skeletal muscle, quercetin increases glucose uptake by enhancing GLUT4 expression in a p38 MAPK and AMPK dependent manner. AMPK, 5 0 AMP-activated protein kinase; ARE, antioxidant response element; GK, glucose kinase; GLUT4, glucose transporter type 4; Nrf2, nuclear transcription factor; p38 MAPK, p38 mitogen-activated protein kinases (Dietz & Santos-Burgoa, 2020; Sattar, McInnes, & McMurray, 2020) .

Besides innate immunity, obesity also affects the adaptive immune responses as observed against the influenza virus (Green & Beck, 2017) . Obesity also potentiates many factors including the development of cardiorespiratory and cardiovascular disorders as well as adverse cardio-renal consequences (Sattar et al., 2020) . All these observations confirm the seriousness and adverse impacts of obesity in COVID-19 patients. In HFD fed mice, quercetin reduced the macrophage infiltration as well as the levels of proinflammatory mediators in adipose tissues (Dong et al., 2014) . Moreover, in a study on healthy male smokers, the supplementation of quercetin dihydrate capsule (100 mg/day for 10 weeks) decreased the levels of total cholesterol and LDL-cholesterol in serum compared to the placebo control group (K. H. Lee et al., 2011) .

Quercetin (150 mg/day) reduced the waist size and triacylglycerol concentration in overweight-obese subjects (Pfeuffer et al., 2013) . A randomized, double-blind, placebo-controlled study demonstrated that supplementation of quercetin (100 mg/day) for 12 weeks to obese subjects significantly decreased the total body fat and reduced the body mass index (BMI) (J. S. Lee, Cha, Lee, & Yim, 2016) .

In conclusion, quercetin exhibits pleiotropic beneficial effects against obesity in preclinical models. To date, no studies have been published on the effect of quercetin in obese individuals affected by COVID-19.

Hemostasis is a highly regulated, orchestrated localized physiological process that checks to bleed at the injury site by the formation of a clot (Gale, 2011) . Any kind of aberration in hemostasis may result in extensive thrombosis associated with microvascular injury in affected organs including the lungs (Ackermann et al., 2020) and even severe intravascular coagulation (Tang, Li, Wang, & Sun, 2020) . Hypercoagulability is one of the common manifestations of COVID-19 which is associated with disease severity (G. Chen et al., 2020) . Elevated levels of plasmin, due to diabetes and other comorbidities, support the virus binding to ACE2 as well as entry into the cells as In conclusion, based on the scientific literature available it can be concluded that there is scant clinical data to support the role of quercetin as an anti-thrombin and anti-fibrinogen agent.

Hypertension or high blood pressure is defined as the presence of a chronic rise in systemic arterial pressure above a certain threshold value (Oparil et al., 2018) . Nearly 45% of the world's adult population is at risk, particularly the people with an age above 60 years. Although Various experimental studies and clinical trials demonstrated that quercetin can exert anti-hypertensive effects through different mechanisms. Duarte et al. (2001) observed that quercetin reduced oxidative stress in spontaneously hypertensive rat models, mimicking hypertension in humans. In a similar study on spontaneously hypertensive rats, quercetin decreased blood pressure and reinstated F I G U R E 4 Anti-adipogenesis activity of quercetin. Quercetin exerts a suppressive effect on fat accumulation by activating HSL which converts TGs to FFAs. Moreover, it also stimulates the expression of UCP1 to increase energy expenditure, an important player in the antiobesity phenomenon. Furthermore, quercetin also restricts pre-adipocyte differentiation, adipogenesis, and inflammation by inhibiting MAPK mediated signaling and its downstream factors like PPARγ and CREB. Quercetin opposes the anti-apoptotic effect of ERK1/2 signaling to promote apoptosis in mature adipocytes and thereby displays its anti-obesity potential. Furthermore, quercetin also increases cholesterol efflux from macrophages to prevent foam cell formation via activation of the PPARγ-ABCA1 pathway and thereby lowers the risk of atherosclerosis. ABCA1, ATP-binding cassette transporter A1; AC, adenylyl cyclase; Bcl-2, B-cell lymphoma 2; cAMP, cyclic adenosine monophosphate; CREB, CCAAT/enhancer-binding protein; DG, diglycerides; ERK, extracellular-signal-regulated kinase; FFAs, free fatty acids; HSL, hormone-sensitive lipase; IR, insulin receptor; LEP-R, leptin receptor; MAPK, mitogen-activated protein kinase; MEK, ERK kinase; MG, monoglycerides; PGC1 α, peroxisome proliferator-activated receptor gamma coactivator 1-α; PKA, protein kinase A; PPARγ, peroxisome proliferator-activated receptor γ; TGs, triglycerides; UCP1, uncoupling protein 1 endothelial dysfunction (Galindo et al., 2012) . Häckl, Cuttle, Dovichi, Lima-Landman, and Nicolau (2002) observed that quercetin reduced the blood pressure induced by intravenous infusion of angiotensin I in Wistar rats and reduced the ACE activity by 31% as compared to baseline. The anti-ACE activity could be due to the presence of the catechol group in the B-ring of flavonoids, which may exert a chargecharge interaction with the Zn 2+ ion in the ACE active site (Guerrero et al., 2012) . Mackraj, Govender, and Ramesar (2008) suggested that quercetin lowers blood pressure through mechanisms, such as downregulation of the angiotensin-I receptor in the kidney, enhanced urine volume, and augmented urinary sodium excretion. Serban et al. (2016) in their meta-analysis observed that other possible mechanisms by which quercetin exhibits anti-hypertensive properties include improvement in vascular function (Yamamoto & Oue, 2006) , enhancing the endothelial nitric oxide (NO) synthase activity, and reduction of NADPH oxidase activity (Sanchez et al., 2006) , decreasing endothelin-1 expression (Nicholson, Tucker, & Brameld, 2008) and maintaining the balance between circulating endothelin-1 and NO (Sanchez et al., 2006) . Among the several polyphenols tested, quercetin and its metabolites were the most effective in inhibiting recombinant human (rh) ACE2 in vitro (P. P. Liu et al., 2020) .

In conclusion, there is robust data to support the antihypertensive effects of quercetin. More clinical studies are needed to investigate the effect of dietary polyphenol intake on ACE2 as well as on blood pressure in healthy as well as COVID-19 patients.

Possible applicative outcomes of natural bioactive compounds, such as quercetin, on health, are limited by their low bioavailability after oral administration. Multiple studies have shown that quercetin and its methylated derivatives with an intact flavonol structure (isorhamnetin, tamarixetin) are present only in the conjugated form, mainly glucuronide and sulfate conjugates, and not as free aglycones (Egert et al., 2008) . Rich, Buchweitz, Winterbone, Kroon, and Wilde (2017) reported poor oral bioavailability of quercetin after a single oral dose due to macronutrient absorption. Quercetin and its derivatives are transformed into various metabolites such as the smaller phenolics by intestinal enzymes and bacteria (D. H. Kim, Kim, Park, & Han, 1999) . Quercetin is also metabolized in the liver into methyl, glucuronide, and sulfate metabolites, which circulate in plasma (Lotito, Zhang, Yang, Crozier, & Frei, 2011) , and hence the F I G U R E 5 Anti-coagulatory effect of quercetin. The TF-dependent (extrinsic) pathway is the main contributor to the induction of thrombotic events in physiological and pathological conditions through the involvement of several coagulatory factors. Quercetin has been observed to down-regulate the expression of TF which eventually inhibits the activation of factor X (inactive) to factor Xa (active), responsible for thrombin and fibrin clot formation. Quercetin can also directly hinder platelet aggregation, another component for thrombosis by inhibiting factor Va (active). Xa, active factor Xa; TF, tissue factor; VIIa, active factor VIIa; Va, active factor Va concentration of quercetin metabolites was observed to be lower in the liver than that of blood plasma .

Low bioavailability of the unmodified quercetin as compared to its metabolites in the systemic circulation, suggests extensive firstpass metabolism by gut and/or liver (Ader, Wessmann, & Wolffram, 2000; Oliveira, Watson, & Grant, 2002) . Elevated concentration of conjugated quercetin in the bile through biliary excretion (Bravo, 1998; Y. Liu, Liu, Dai, Xun, & Hu, 2003) may result in elevated plasma metabolite concentrations (X. Chen, Yin, Zuo, & Chow, 2005) . Hollman, de Vries, van Leeuwen, Mengelers, and Katan (1995) detected that in ileostomized but healthy volunteers, 24% of quercetin was absorbed after consumption of quercetin aglycone (100 mg/ day). Intake of quercetin along with vitamin C, folate, and additional flavonoids improved its bioavailability (Harwood et al., 2007; Manach, Mazur, & Scalbert, 2005) . Elimination of quercetin from the human body is quite slow with a testified half-life of 11 to 28 hr, and an average terminal half-life of 3.5 hr (Manach et al., 2005) .

Quercetin and its derivatives remain unaffected by gastric juice in the stomach, are hydrolyzed by beta-glucosidases to the aglycone form and are absorbed in the upper region of the small intestinal . According to Dabeek and Marra (2019) , the structure of sugar moieties had a significant impact on the absorption of these compounds. Sodium-dependent glucose transporter (SGLT 1) transports the quercetin glucosides actively into enterocytes (Williamson, Kay, & Crozier, 2018) .

Quercetin bioavailability is also affected by the presence of other food components such as lipids, proteins, and carbohydrates in the intestine (H. Zhang et al., 2014) . Interestingly, a typical Western-type diet of humans contains enough dietary fat to facilitate the absorption of quercetin (Lesser, Cermak, & Wolffram, 2004) . Being a lipophilic compound, absorption of quercetin aglycone across the intestinal membranes is higher than its glycosidic forms since it takes place by simple diffusion (Nemeth & Piskula, 2007) . Enhanced bioavailability and assimilation of quercetin if consumed with a fatty diet is probably due to its inclusion into lipid micelles (Guo et al., 2013) .

In conclusion, the metabolism of quercetin, its biotransformation, bioavailability, and tissue distribution have been largely studied. It remains to be determined how the low circulating concentrations of quercetin aglycone can explain its biological effects. It is desirable that the low bioavailability of quercetin can be bypassed or ameliorated by innovative drug delivery systems (e.g., nanoparticles, lipid nanoparticles, liposomes, micelles, carbon nanotubes, etc.), a field constantly growing that is beyond the scope of the present work.

Experimental and preclinical studies along with prospective masked randomized clinical trials will likely be relevant to answering quercetin effectiveness/mechanisms against SARS-CoV-2 related questions. In fact, currently (as of January 9, 2022) 14 interventional clinical trials are underway for evaluation of quercetin efficacy as prophylaxis and treatment option against COVID-19 as drug/by supplementing diet (Table 1 , source: https://clinicaltrials.gov/). Among these, six studies have been completed and eight are ongoing, but in the large part of the former, the results are still awaited. However, one study, namely NCT04578158, (Table 1) Table 1 ). The rationale behind several of these trials is the hypothesis that quercetin may reinforce the natural immune system making it more competent to counteract the progression of COVID-19 in the early stage of infection. On the other hand, the administration of Psidii guava extract (2 capsules three times daily) has been suggested to shorten the duration of COVID-19 seroconversion in mild and symptomless cases (NCT04810728, Table 1 ).

The combined effects of quercetin plus zinc, vitamin C, and bromelain are under investigation in COVID-19 patients (NCT04468139 ;   Table 1 ), while its capacity in improving the efficacy and safety of hydroxychloroquine for the prevention and treatment of COVID-19

infection is also ongoing (NCT04590274 ; Table 1 ). Furthermore, an RCT is exploring the efficacy and safety of quercetin derivate, isoquercetin (IQC-950AN) in combination with standard care or masitinib in confirmed moderate and severe COVID-19 patients (NCT04536090 and NCT04622865; Table 1 ). In fact, isoquercetin prevents the activity of disulfide isomerase (PDI) which is directly involved in the formation of the clots and also reduces D-dimer, an interpreter of SARS-COV-2 infection mediated thrombosis severity. The implementation of masitinib, a tyrosine kinase inhibitor, may hamper the production of the "cytokine storm" by blocking mast cells and macrophages activity. Another comparative RCT is evaluating the efficacy and safety of NASAFYTOL ® containing quercetin along with curcumin and vitamin D on hospitalized COVID-19 patients (NCT04844658 ; Table 1 ).

NASAFYTOL ® is designed to augment the bioavailability of the bioactive components in humans and it is also under investigation in patients with early COVID-19 symptoms to prove its capacity to ameliorate viral clearance (NCT05008003; Table 1 ).

In conclusion, a wide array of quercetin's therapeutic properties has prompted various clinical trials to study its effect in COVID-19. Overall, these clinical trials are rigorously trying to investigate the prophylactic and therapeutic index of quercetin during COVID-19 infection. The present review is tempting to suggest that, based on circumstantial scientific evidence and preliminary clinical data, the flavonoid quercetin can ameliorate comorbid conditions (COPD, diabetes, obesity, coagulopathy, hypertension, and aging), which increase disease severity and mortality in COVID-19 patients ( Figure 6 ). The rationale behind many of the cited studies in the present work involving quercetin regards the multifaceted beneficial aspects of quercetin supplementation that, along with conventional therapies, might play some role in ameliorating COVID-19 infection and symptoms acting in concert on two parallel and independent paths: inhibiting key factors responsible for SARS-CoV-2 infections and mitigate the clinical manifestations of the disease in patients with comorbidities or in those subjects who are more prone to severe COVID-19 progression. However, in both cases, we are in a very early, although promising, phase of knowledge and in this review, we tried to analyze the strengths and weaknesses of this hypothesis.

In the last 2 years, we assisted in a proliferation of studies dealing with the anti-COVID-19 properties of natural compounds or extracts and quercetin falls perfectly in this category, as we discussed above. "quercetin group," the protection to contract the COVID-19 infection was 14% compared to the "placebo group" and the complete clinical remission was shorter (7 vs. 15 days) in the former with respect to the latter (Rondanelli et al., 2022) . Finally, in a different study, COVID-19 patients receiving for 7 days 1 g of quercetin plus conventional antiviral drugs (remdesivir or favipiravir) showed reduced levels of critical markers involved in COVID-19 severity (e.g., ALP, q-CRP, and LDH) (Shohan et al., 2022) .

Although all the above-mentioned clinical studies suffer from the same constraints, for example, small sample size, narrow characteristics of the enrolled subjects, short duration of the trial, a lim- Similarly, it is tempting to speculate that quercetin might be considered as a potential therapeutic/prophylaxis option for COVID-19

subjects, due to its reported cholesterol-lowering ability (A. C. Li & Glass, 2002; M. Zhang et al., 2016) similarly to fenofibrate, a cholesterol-lowering drug, which demonstrated promising effects against SARS-CoV-2 replication as well as pathogenesis (Ehrlich et al., 2020) .

In the Introduction, we mentioned the immunomodulatory and immune-boosting properties of quercetin that have been further discussed in the following paragraphs linking them to the antiinflammatory effects of the molecule. The interesting and new F I G U R E 6 Representation of the pleiotropic beneficial effects of quercetin refers to different comorbid and physiological conditions, which are thought to contribute to the severity of SARS-CoV-2 infection. ACE2, angiotensin-converting enzyme 2; AMPK, 5 0 AMP-activated protein kinase; COPD, chronic obstructive pulmonary disease; ERK, extracellular-signal-regulated kinase; GK, glucose kinase; JNK1, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinases; NO, nitric oxide; PDE4, phosphodiesterase 4; ROS, reactive oxygen species; SARS-Co-V, severe acute respiratory syndrome coronavirus; SASP, senescence-associated secretory phenotype theory, named "WE Medicine," indicates the combination of the medical principles regulating Western and Eastern medicine and can help to explain the beneficial effects of natural compounds. In this context, based on the conclusions of a very recent and distinguished article (Shi et al., 2022) , it can be hypothesized that the synergistic effects of natural agents can mitigate and/or compensate the drawbacks due to their low absorption, distribution, and metabolism favoring their immune-pharmaceutical effects in modulating the immune effectors'

functions during COVID-19.

In conclusion, the present review is tempted to analyze the strengths and weaknesses of the potential anti-COVID-19 effects of quercetin. Although several limitations have been clearly deciphered and commented on, we do believe that these draw- 

The authors declare no conflicts of interest. 

Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19

Bioavailability and metabolism of the flavonol quercetin in the pig

The anti-obesity effect of quercetin is mediated by the AMPK and MAPK signaling pathways

Dexamethasone in the era of COVID-19: Friend or foe? An essay on the effects of dexamethasone and the potential risks of its inadvertent use in patients with diabetes

COVID-19 and coagulation: Bleeding and thrombotic manifestations of SARS-CoV-2 infection

Diagnosis and classification of diabetes mellitus

The AMPK enzyme-complex: From the regulation of cellular energy homeostasis to a possible new molecular target in the management of chronic inflammatory disorders

Quercetin can reduce insulin resistance without decreasing adipose tissue and skeletal muscle fat accumulation

Intakes of total and individual flavonoids by US adults

The pharmacological activity, biochemical properties, and pharmacokinetics of the major natural polyphenolic flavonoid: Quercetin. Foods

Natural polyphenols as Immunomodulators to rescue immune response homeostasis: Quercetin as a research model against severe COVID-19

Quercetin alleviates hypercholesterolemic diet induced inflammation during progression and regression of atherosclerosis in rabbits

Use of quercetin in animal feed: Effects on the P-gp expression and pharmacokinetics of orally administrated enrofloxacin in chicken

Medicinal Chemistry Research: An International Journal for Rapid Communications on Design and Mechanisms of Action of Biologically Active Agents

From causes of aging to death from COVID-19

Polyphenols: Chemistry, dietary sources, metabolism, and nutritional significance

Effectiveness of supplementation with quercetin-type flavonols for treatment of viral lower respiratory tract infections: Systematic review and metaanalysis of preclinical studies

Antidiabetic effect of quercetin: A systematic review and metaanalysis of animal studies

Senolytics reduce coronavirusrelated mortality in old mice

Quercetin suppresses the progression of atherosclerosis by regulating MST1-mediated autophagy in ox-LDL-induced RAW264.7 macrophage foam cells

Inhibitory effects of quercetin derivatives on phosphodiesterase isozymes and high-affinity [ 3 H]-rolipram binding in guinea pig tissues

Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus

Clinical and immunological features of severe and moderate coronavirus disease 2019

Binding interaction of quercetin-3-β-galactoside and its synthetic derivatives with SARS-CoV 3CL pro : Structure-activity relationship studies reveal salient pharmacophore features

Therapeutic effects of quercetin on inflammation, obesity, and type 2 diabetes. Mediators of Inflammation

Pharmacokinetics and modeling of quercetin and metabolites

In vitro antiviral activities of Caesalpinia pulcherrima and its related flavonoids

Quercetin upregulates uncoupling protein 1 in white/brown adipose tissues through sympathetic stimulation

Comparative effect of quercetin and quercetin-3-O-β-d-glucoside on fibrin polymers, blood clots, and in rodent models

Definition, epidemiology and classification of diabetes in children and adolescents. Pediatric Diabetes

Part of quercetin absorbed in the small intestine is conjugated and further secreted in the intestinal lumen

Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD

Antimicrobial activity of flavonoids

Quercetin attenuates acute lung injury caused by cigarette smoke both in vitro and in vivo

Zinc ionophore activity of quercetin and epigallocatechin-gallate: From Hepa 1-6 cells to a liposome model

Dietary quercetin and kaempferol: Bioavailability and potential cardiovascular-related bioactivity in humans

Quercetin but not quercitrin ameliorates tumor necrosis factor-alpha-induced insulin resistance in C2C12 skeletal muscle cells

Effects of propolis flavonoids on virus infectivity and replication

A role for quercetin in coronavirus disease 2019 (COVID-19)

Quercetin, a lead compound against type 2 diabetes ameliorates glucose uptake via AMPK pathway in skeletal muscle cell line

Endothelins in cardiovascular biology and therapeutics

Quercetin and its derivates as antiviral potentials: A comprehensive review

Possible therapeutic effects of adjuvant quercetin supplementation against early-stage COVID-19 infection: A prospective, randomized, controlled, and open-label study

Potential clinical benefits of quercetin in the early stage of COVID-19: Results of a second, pilot, randomized, controlled and open-label clinical trial

Obesity and its implications for COVID-19 mortality

Safety-assessment of 3-methoxyquercetin as an antirhinoviral compound for nasal application: Effect on ciliary beat frequency

Role of CD8 T cell replicative senescence in human aging and in HIV-mediated immunosenescence

Quercetin reduces obesity-associated ATM infiltration and inflammation in mice: A mechanism including AMPKα1/SIRT1

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

Immune mechanisms of hypertension

Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats

Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans

The SARS-CoV-2 transcriptional metabolic signature in lung epithelium

Survival rate in hypertensive patients with COVID-19

Quercetin prevents rhinovirus-induced progression of lung disease in mice with COPD phenotype

Effect of angiotensinconverting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2

Continuing education course #2: Current understanding of hemostasis

Glucuronidated quercetin lowers blood pressure in spontaneously hypertensive rats via deconjugation

Definition, epidemiology, risk factors

Quercetin prevents progression of disease in elastase/LPS-exposed mice by negatively regulating MMP expression

Tripartite combination of candidate pandemic mitigation agents: vitamin D, quercetin, and estradiol manifest properties of medicinal agents for targeted mitigation of the COVID-19 pandemic defined by genomics-guided tracing of SARS-CoV-2 targets in human cells

Clinical and molecular markers in COPD

Obesity impairs the adaptive immune response to influenza virus

Clinical characteristics of coronavirus disease 2019 in China

Inhibition of angiotensin-converting enzyme activity by flavonoids: Structure-activity relationship studies

Dietary fat increases quercetin bioavailability in overweight adults

Inhibition of angiotesin-converting enzyme by quercetin alters the vascular response to brandykinin and angiotensin I

Quercetin inhibits glucose transport by binding to an exofacial site on GLUT1

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease

A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food and Chemical Toxicology

The serial cultivation of human diploid cell strains

Dietary quercetin supplementation in mice increases skeletal muscle PGC1α expression, improves mitochondrial function and attenuates insulin resistance in a time-specific manner

COVID-19 and COPD: A narrative review of the basic science and clinical outcomes

Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers

Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man

The epidemiology of obesity: A big picture

A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19)

COVID-19 patients with hypertension have more severe disease: A multicenter retrospective observational study

Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans

Populationlevel COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters

Elevated plasmin(ogen) as a common risk factor for COVID-19 susceptibility

Quercetin reduces high-fat diet-induced fat accumulation in the liver by regulating lipid metabolism genes

Onion peel extracts ameliorate hyperglycemia and insulin resistance in high fat diet/streptozotocin-induced diabetic rats

Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes

Antiviral effect of flavonoids on human viruses

Neuroprotective effects of quercetin in Alzheimer's disease

Metabolism of quercitrin by human intestinal bacteria and its relation to some biological activities

Effects of naturallyoccurring flavonoids and biflavonoids on epidermal cyclooxygenase and lipoxygenase from guinea-pigs

Quercetin attenuates fasting and postprandial hyperglycemia in animal models of diabetes mellitus

Cellular senescence: A translational perspective

Senolytic drugs: From discovery to translation

Ink4a/Arf expression is a biomarker of aging

Natural history and mechanisms of COPD

Onion peel extract reduces the percentage of body fat in overweight and obese subjects: A 12-week, randomized, double-blind, placebo-controlled study. Nutrition Research and Practice

Effects of daily quercetin-rich supplementation on cardiometabolic risks in male smokers

Virus-induced senescence is a driver and therapeutic target in COVID-19

Arterial hypertension and the risk of severity and mortality of COVID-19

Bioavailability of quercetin in pigs is influenced by the dietary fat content

The macrophage foam cell as a target for therapeutic intervention

The association of hypertension with the severity and mortality of COVID-19 patients: Evidence based on adjusted effect estimates

The science underlying COVID-19: Implications for the cardiovascular system

Enteric disposition and recycling of flavonoids and ginkgo flavonoids

The hallmarks of aging

Metabolic conversion of dietary flavonoids alters their anti-inflammatory and antioxidant properties

Polygonum aviculare L. extract and quercetin attenuate contraction in airway smooth muscle

The antihypertensive effects of quercetin in a salt-sensitive model of hypertension

Exploring the relevance of senotherapeutics for the current SARS-CoV-2 emergency and similar future global health threats

Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation

Polyphenols and prevention of cardiovascular diseases

Comparison of the bioavailability of quercetin and catechin in rats

Projections of global mortality and burden of disease from

Immunomodulatory properties of quercetin-3-O-α-L-rhamnopyranoside from Rapanea melanophloeos against influenza a virus

Markers of cellular senescence are elevated in murine blastocysts cultured in vitro: Molecular consequences of culture in atmospheric oxygen

Flavonoids inhibit the amidolytic activity of human thrombin

Managing hypertension during the COVID-19 pandemic

Food content, processing, absorption and metabolism of onion flavonoids

Quercetin and its derivative Q2 modulate chromatin dynamics in adipogenesis and Q2 prevents obesity and metabolic disorders in rats

Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris

Effects of dietary polyphenols on gene expression in human vascular endothelial cells

Dual roles of quercetin in platelets: Phosphoinositide-3-kinase and MAP kinases inhibition, and cAMP-dependent vasodilator-stimulated phosphoprotein stimulation. Evidence-Based Complementary and Alternative Medicine: eCAM

Metabolism of quercetin and kaempferol by rat hepatocytes and the identification of flavonoid glycosides in human plasma. Xenobiotica; The Fate of Foreign Compounds in Biological Systems

Evaluation of polyphenols from Broussonetia papyrifera as coronavirus protease inhibitors

Hyperglycemia induces differential change in oxidative stress at gene expression and functional levels in HUVEC and HMVEC

Therapeutic potential of quercetin as a cardiovascular agent

Molecular and functional resemblance of dexamethasone and quercetin: A paradigm worth exploring in dexamethasone-nonresponsive COVID-19 patients

Effect of quercetin on traits of the metabolic syndrome, endothelial function and inflammation in men with different APOE isoforms. Nutrition, Metabolism, and Cardiovascular Diseases: NMCD

Venous thromboembolism in COVID-19 patients

Comparison of confirmed COVID-19 with SARS and MERS cases -Clinical characteristics, laboratory findings, radiographic signs and outcomes: A systematic review and meta-analysis

Is diabetes mellitus a risk factor for COronaVIrus Disease 19 (COVID-19)?

Antioxidant therapies in COPD

Oxidative stress and redox regulation of lung inflammation in COPD

The role of zinc in antiviral immunity

Dexamethasone in hospitalized patients with Covid-19

Senescence: An antiviral defense that is tumor suppressive?

Towards an understanding of the low bioavailability of quercetin: A study of its interaction with intestinal lipids

Promising effects of 3-month period of quercetin Phytosome ® supplementation in the prevention of symptomatic COVID-19 disease in healthcare workers: A pilot study

Quercetin ameliorates oxidative stress, inflammation and apoptosis in the heart of streptozotocin-nicotinamide-induced adult male diabetic rats. Biomedicine and Pharmacotherapy

A blueprint for characterizing senescence

New-onset diabetes in Covid-19

Roles of flavonoids against coronavirus infection

Exploring death receptor pathways as selective targets in cancer therapy

Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL pro inhibition

Perspectives on plant flavonoid quercetin-based drugs for novel SARS-CoV-2. Beni-Suef University

Quercetin downregulates NADPH oxidase, increases eNOS activity and prevents endothelial dysfunction in spontaneously hypertensive rats

COVID-19 and chronological aging: Senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection

Obesity is a risk factor for severe COVID-19 infection: Multiple potential mechanisms

Potential nutraceuticals for COVID-19. Nutrition and Dietary Supplements

Role of diet in chronic obstructive pulmonary disease prevention and treatment

Effects of quercetin on blood pressure: A systematic review and meta-analysis of randomized controlled trials

Oral Chinese herbal medicine on immune responses during coronavirus disease 2019: A systematic review and meta-analysis

Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity

The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial

Geroscience and the coronavirus pandemic: The whacka-mole approach is not enough

Impact of COVID-19 and comorbidities on health and economics: Focus on developing countries and India. Diabetes & Metabolic Syndrome

Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: The GOLD science committee report 2019

Cigarette smoke exposure and inflammatory signaling increase the expression of the SARS-CoV-2 receptor ACE2 in the respiratory tract

Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg 9 bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration

Associations of dietary flavonoids with risk of type 2 diabetes, and markers of insulin resistance and systemic inflammation in women: A prospective study and cross-sectional analysis

The metabolites of the dietary flavonoid quercetin possess potent antithrombotic activity, and interact with aspirin to enhance antiplatelet effects

Renal intramedullary infusion of tempol normalizes the blood pressure response to intrarenal blockade of heme oxygenase-1 in angiotensin II-dependent hypertension

Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activation

Quercetin increases macrophage cholesterol efflux to inhibit foam cell formation through activating PPARγ-ABCA1 pathway

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Quercetin acutely relaxes airway smooth muscle and potentiates β-agonist-induced relaxation via dual phosphodiesterase inhibition of PLCβ and PDE4

Coronavirus biology and replication: Implications for SARS-CoV-2

Circulating tissue factor procoagulant activity is elevated in stable moderate to severe chronic obstructive pulmonary disease

Accuracy of a symptom-based approach to identify hypertensive emergencies in the emergency department

Does comorbidity increase the risk of patients with COVID-19: Evidence from meta-analysis

Senescent human fibroblasts resist programmed cell death, and failure to suppress bcl2 is involved

The role of high cholesterol in agerelated COVID19 lethality

The bioavailability, transport, and bioactivity of dietary flavonoids: A review from a historical perspective

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet

Antihypertensive effect of quercetin in rats fed with a high-fat high-sucrose diet

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Clinical characteristics and outcomes of patients with severe covid-19 with diabetes

Anti-diabetic effect of cotreatment with quercetin and resveratrol in streptozotocin-induced diabetic rats

Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells

Interaction of plant phenols with food macronutrients: Characterisation and nutritional-physiological consequences

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Quercetin regulates hepatic cholesterol metabolism by promoting cholesterol-to-bile acid conversion and cholesterol efflux in rats

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study

Clinical characteristics of 3062 COVID-19 patients: A meta-analysis

Association of Blood Glucose Control and Outcomes in patients with COVID-19 and pre-existing type 2 diabetes

Diabetes and its drivers: The largest epidemic in human history?

A critical evaluation of risk to reward ratio of quercetin supplementation for COVID-19 and associated comorbid conditions